粒细胞集落刺激因子治疗重症酒精性肝炎患者疗效的Meta分析*

doi:10.3969/j.issn.1672-5069.2023.02.015

摘要/Abstract

摘要： 目的评估应用粒细胞集落刺激因子(G-CSF)治疗重症酒精性肝炎(SAH)患者的临床疗效。方法应用计算机检索PubMed、Embase、中国期刊全文数据库、万方数据库、中文科技期刊数据库、中华医学会数字化期刊库自建库至2022年5月中、英文文献,同时手检相关期刊和会议论文集,对采用随机对照试验应用G-CSF治疗的SAH患者资料进行Meta分析,评估90 d生存率,应用 RevMan 5.4软件进行分析。结果共纳入5项研究,包括198例患者,除了标准药物治疗外,其中98例接受了G-CSF治疗,另100例接受了安慰剂治疗;经Meta分析,G-CSF治疗组90 d生存75例(76.5%),显著高于对照组的28例(28.0%),差异有统计学意义(RR=2.74,95 % CI:1.96～3.83,P＜0.01),各研究间无显著性异质性(P= 0.61,I²= 0%)。结论应用G-CSF治疗SAH患者可显著提高短期生存率,值得进一步研究。

关键词: 重症酒精性肝炎, 粒细胞集落刺激因子, 治疗, Meta分

Abstract: Objective The aim of this study was to meta analyze the clinical efficacy of granulocyte colony stimulating factor (G-GSF) in treatment of patients with severe alcoholic hepatitis (SAH). Methods The PubMed, Embase, Chinese Journal Full-text Database, Wanfang Database, Chinese Science and Technology Journal Database, Chinese Medical Association digital Journal Database in Chinese and English were searched from the establishment of databases to May 2022. At the same time, we handed check related journals and conference proceedings. The randomized controlled trials (RCT) on the administration of G-CSF in the treatment of patients with SAH were analyzed to evaluate the 90-day survival rate in both G-CSF-treated and control groups, and the data were analyzed by RevMan 5.4. Results A total of 198 patients were included in 5 RCT studies obtained; at the base of conventional medical support therapy, 98 patients received G-CSF and another 100 patients received placebo; by the Meta-analysis, the 90-day survival in the G-CSF-treated group was 76.5%, much higher than 28.0% in the control group, and the difference was statistically significant (RR=2.74,95% CI: 1.96-3.83, P＜0.01); there was no significant heterogeneity among the five studies (P=0.61, I²=0%). Conclusion In patients with SAH, the 90-day survival rate is significantly improved when the G-CSF treatment is given, which needs further clinical investigation.

Key words: Severe alcoholic hepatitis, Granulocyte colony-stimulating factor, Therapy, Meta-analysis

张龙玉, 牟丹蕾, 李侗曾, 张佳莹, 梁连春. 粒细胞集落刺激因子治疗重症酒精性肝炎患者疗效的Meta分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 210-213.

Zhang Longyu, Mou Danlei, Li Tongzeng, et al.. Clinical efficacy of granulocyte colony stimulating factor in the treatment of patients with severe alcoholic hepatitis:a Meta-analysis[J]. Journal of Practical Hepatology, 2023, 26(2): 210-213.

参考文献

[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪肝专家委员会. 酒精性肝病防治指南(2018年更新版). 实用肝脏病杂志, 2018, 21(2): 170-176.
[2] Carithers RL Jr, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med, 1989, 110(9): 685-690.
[3] Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology, 1978, 75(2): 193-199.
[4] Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med, 2009, 360(26): 2758-2769.
[5] Crabb DW, Im GY, Szabo G, et al. Diagnosis and treatment of alcohol-associated liver diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology, 2020, 71(1): 306-333.
[6] Singal AK, Bataller R, Ahn J, et al. ACG Clinical Guideline: Alcoholic liver disease. Am J Gastroenterol, 2018, 113(2): 175-194.
[7] Mathurin P, O'Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut, 2011, 60(2): 255-260.
[8] Thursz MR, Richardson P, Allison M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med, 2015, 372(17): 1619-1628.
[9] Singh S, Murad MH, Chandar AK, et al. Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: A systematic review and network Meta-analysis. Gastroenterology, 2015, 149(4): 958-970, e12.
[10] Vergis N, Atkinson SR, Knapp S, et al. In patients with severe alcoholic hepatitis, prednisolone increases susceptibility to infection and infection-related mortality, and is associated with high circulating levels of bacterial DNA. Gastroenterology, 2017, 152(5): 1068-1077, e4.
[11] Singh V, Keisham A, Bhalla A, et al. Efficacy of granulocyte colony-stimulating factor and N-acetylcysteine therapies in patients with severe alcoholic hepatitis. Clin Gastroenterol Hepatol, 2018, 16(10): 1650-1656, e2.
[12] Spahr L, Lambert JF, Rubbia-Brandt L, et al. Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology, 2008, 48(1): 221-229.
[13] Mark AL, Sun Z, Warren DS, et al. Stem cell mobilization is life saving in an animal model of acute liver failure. Ann Surg, 2010, 252(4): 591-596.
[14] 周培, 于淙, 渠淑云. 集落刺激因子治疗终末期酒精性肝病的临床对照研究. 肝脏, 2020, 25(5): 521-524.
[15] Shasthry SM, Sharma MK, Shasthry V, et al. Efficacy of granulocyte colony-stimulating factor in the management of steroid-nonresponsive severe alcoholic hepatitis: A double-blind randomized controlled trial. Hepatology, 2019, 70(3): 802-811.
[16] Sharma A, Setia A, Rai RR. Effect of granulocyte colony-stimulating factor (G-CSF) on mortality and complications viz. sepsis, encephalopathy, hepatorenal syndrome, and gastrointestinal bleed in severe alcoholic hepatitis: a randomized controlled study. United Eur Gastroenterol, 2017, 5: A17.
[17] Singh V, Sharma AK, Narasimhan RL, et al. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am J Gastroenterol, 2014, 109(9): 1417-1423.
[18] Singal AK, Salameh H, Singal A, et al. Management practices of hepatitis C virus infected alcoholic hepatitis patients: A survey of physicians. World J Gastrointest Pharmacol Ther, 2013, 4(2): 16-22.
[19] 张岱, 王炳元. 酒精性肝炎的诊断与挑战. 实用肝脏病杂志. 2019, 22(2): 153-155.
[20] 范文瀚, 罗怡平, 李成忠. 糖皮质激素应用于肝衰竭治疗机制及其临床时机的把握. 实用肝脏病杂志, 2020, 23(1): 7-9.
[21] Singal AK, Kamath PS, Gores GJ, et al. Alcoholic hepatitis: current challenges and future directions. Clin Gastroenterol Hepatol, 2014, 12(4): 555-564; quiz e31-32.
[22] Dubuquoy L, Louvet A, Lassailly G, et al. Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis. Gut, 2015, 64(12): 1949-1960.
[23] Gustot T. Beneficial role of G-CSF in acute-on-chronic liver failure: effects on liver regeneration, inflammation/immunoparalysis or both? Liver Int, 2014, 34(4): 484-486.
[24] Moreau R, Rautou PE. G-CSF therapy for severe alcoholic hepatitis: targeting liver regeneration or neutrophil function? Am J Gastroenterol, 2014, 109(9): 1424-1426.
[25] Dale DC, Crawford J, Klippel Z, et al. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer, 2018, 26(1): 7-20.

粒细胞集落刺激因子治疗重症酒精性肝炎患者疗效的Meta分析^*

Clinical efficacy of granulocyte colony stimulating factor in the treatment of patients with severe alcoholic hepatitis:a Meta-analysis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	邓玉婷, 周俊英. 布加综合征诊治研究进展[J]. 实用肝脏病杂志, 2023, 26(2): 156-159.
[2]	尹雯, 鲁科翔, 王雪, 王彩艳. 恩替卡韦联合苦参素治疗HBeAg阳性慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 173-176.
[3]	魏丽, 刘博, 赵楠, 梁丽君. 恩替卡韦抗病毒治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者病毒学应答情况分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 181-184.
[4]	凌佳慧, 倪美鑫, 韩黎黎, 卫栋萍, 戴轶伟, 陈婷婷. 异甘草酸镁治疗自身免疫性肝炎患者血清细胞因子水平变化^*[J]. 实用肝脏病杂志, 2023, 26(2): 214-217.
[5]	李艳芬, 张晓文, 王艳茹, 齐慧芳, 支姗. 应用奥贝胆酸和贝特类药物治疗对熊去氧胆酸治疗不完全应答的原发性胆汁性胆管炎患者临床研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 226-229.
[6]	徐菁, 刘坤, 马竹芳. 异甘草酸镁防治接受化疗的晚期胃癌患者肝肾功能损伤临床研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 234-237.
[7]	程洋, 张峰, 王曦旋, 尹晓春, 肖江强, 张明, 王雷, 邹晓平, 诸葛宇征. 普萘洛尔与卡维地洛预防肝硬化患者并发食管胃静脉曲张破裂出血临床疗效比较^*[J]. 实用肝脏病杂志, 2023, 26(2): 254-257.
[8]	张斌, 赵宇亮, 闫国贝. hUCB-MNCs联合hUC-MSCs静脉输注治疗失代偿期乙型肝炎肝硬化患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 262-265.
[9]	周秋娟, 朱逸明, 马宇航, 陈婷闪. TIPS与PSE术治疗乙型肝炎肝硬化并发脾功能亢进症患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 266-269.
[10]	龚程, 田银生, 刘爽. 不同时间窗手术治疗原发性肝癌自发破裂出血患者2年生存率比较^*[J]. 实用肝脏病杂志, 2023, 26(2): 274-277.
[11]	史浩, 陈勇, 罗斌, 李道明. 微波消融术前阿霉素磁液靶向化疗治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 278-281.
[12]	尹秋实, 王学国, 宋奇锋. 左肝蒂阻断法行完全腹腔镜左半肝切除术与开腹手术治疗肝内外胆管结石患者效果比较^*[J]. 实用肝脏病杂志, 2023, 26(2): 282-285.
[13]	黄姝伦, 贺胜铎, 徐小元, 王化虹. 部分肠内营养联合奥曲肽治疗肝硬化乳糜性腹水1例报告[J]. 实用肝脏病杂志, 2023, 26(2): 290-292.
[14]	黄晓铨, 陈世耀. 重视规范化处理门静脉高压并发食管胃静脉曲张出血^*[J]. 实用肝脏病杂志, 2023, 26(1): 1-3.
[15]	申艳, 陈琳. 内镜治疗食管胃静脉曲张破裂出血及其长期管理^*[J]. 实用肝脏病杂志, 2023, 26(1): 8-10.